Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences is viewed favorably because its leadership in transcatheter aortic valve replacement and its broader surgical, mitral, and tricuspid portfolio give it a durable competitive moat in structural heart disease, a market with few effective alternatives and strong clinical need. The company’s recent quarter showed robust execution, with TAVR revenue of $1.26B (+10.5% y/y ex-FX) and TMTT growth of +45.5% y/y ex-FX, while FY26 guidance was raised to +10-11% revenue growth ex-FX and operating margin is still expected to reach the high end of the 28-29% range. Supportive regulatory and clinical catalysts, including the final TAVR NCD, the PROGRESS trial readout, and next-gen PASCAL launches, could expand procedure volumes and sustain roughly a ~10% long-term growth trajectory, with additional upside from its 60% international sales base and ongoing margin expansion efforts.

Edwards Lifesciences is facing a negative outlook because, despite an impressive Q2 revenue increase to $1,741M and adjusted EPS of $0.78, the stock appears to be priced for sustained perfection, with valuation already near the high end of its large-cap medical device peer group. The company’s reliance on a concentrated set of structural heart franchises, including TAVR at $1,258M and TMTT at $195.9M, leaves results highly dependent on continued execution, favorable clinical data, and uninterrupted adoption of newer therapies, while adjusted gross margin of 77.6% showed some pressure from FX. In addition, about 60% of sales coming from outside the US exposes the business to foreign exchange volatility and cross-border demand swings, and the cited risks of commercial hiccups, regulatory and NCD delays, product recalls, and competition make the current premium less attractive from a fundamental standpoint.